CAMBRIDGE, England,
Dec. 8, 2020 /PRNewswire/
-- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in
life science reagents and tools, announced the opening of a new
16,000 sq ft purpose-fitted facility in Fremont, CA, which will serve as a major new
site for its specialist cell engineering team. This
state-of-the-art facility will enable delivery of engineered cell
lines to power expansion of the ready-to-use portfolio and
facilitate delivery of customization to meet the demanding needs of
research, diagnostic and therapeutic development.
The move follows Abcam's acquisition of the team and its highly
adaptable CRISPR-Cas9-based gene editing platform from Applied Stem
Cell earlier this year. The new facility has received significant
investment from the business and features an extensive suite of
tissue culture labs and is a pivotal part of Abcam's ambitious
growth plans to expand and cement its position in the edited cell
line market.
Jac Price, SVP Manufacturing
and Supply Chain at Abcam, said: "We are excited to be
part of the active and growing biotech community in Fremont with our newest, customized facility.
Our cell engineering team are highly experienced and a
long-established leader in the edited cell lines market. This
facility will enable them to further expand and increase the
provision of a comprehensive cell engineering service for a
variety of different life sciences applications, at both speed and
scale."
This enhanced capability builds upon Abcam's previous
acquisition of an extensive range of knockout cell lines from
Edigene last year. Ready-made KO cell lines play a significant
role in the study and understanding of biological pathways and
disease models. Abcam's gene-edited cell line portfolio and
engineering capability is also supporting the company's
award-winning knockout validation initiative, an integral part of
the organization's ongoing efforts to raise reagent quality
standards across the industry.
Notes to Editors
About Abcam plc
As a global life sciences company, Abcam identifies, develops,
and distributes high-quality biological reagents and tools that are
crucial to research, drug discovery and diagnostics. Working across
the industry, the Company supports life scientists to achieve their
mission, faster.
Abcam partners with life science organizations to co-create
novel binders for use in drug discovery, in vitro
diagnostics and therapeutics, driven by the Company's proprietary
discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is
helping advance the global understanding of biology and causes of
disease, which enables new treatments and improved health. The
Company's pioneering data-sharing approach gives scientists
increased confidence in their results by providing validation, user
comments and peer-reviewed citations for its 110,000 products.
With 13 sites globally, many of Abcam's 1,500-strong team are
located in the world's leading life science research hubs,
complementing a global network of services and support.
To find out more, please
visit www.abcam.com and www.abcamplc.com.
View original
content:http://www.prnewswire.com/news-releases/abcam-reveals-new-cell-engineering-facility-in-bay-area-301188225.html
SOURCE Abcam